Compare Ginkgo Bioworks Holdings Inc (DNA) vs Palo Alto Networks Inc (PANW) Price & Performance

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Palo Alto Networks (PANW) trades at $384.29, down 0.19% on the day, with a bullish technical signal supported by moving averages and strong institutional sentiment. Revenue grew to $9.22B in FY2025, with net income of $1.13B, though valuation ratios like P/E of 333.74 and P/S of 26.64 appear elevated. Recent news highlights AI-driven cybersecurity demand and a China regulatory review, while the company beat EPS estimates in three consecutive quarters.

Outlook remains positive due to robust AI security growth and analyst consensus, but risks include high valuation, integration costs from acquisitions, and geopolitical scrutiny. The stock's proximity to its 52-week high suggests cautious optimism, with upside potential tied to execution on AI initiatives and cybersecurity spending trends.